Legionella pneumophila erythromycin activity

Roxithromycin has similar in vitro activity to erythromycin but enters leucocytes and macrophages more rapidly with higher concentrations in the lysosomal component of the phagocytic cells. It is likely to become an important drug against Legionella pneumophila. Clarithromycin is also of potential value. 

The most important members of this group are erythromycin (Fig. 10.11), oleandomycin, triacetyl-oleandomycin and spiramycin. Erythromycin is active against most Gram-positive bacteria, Neisseria, H. influence and Legionella pneumophila, but not against the Enterobacteriaceae its activity is... 

C. Clinical Uses Erythromycin is effective in the treatment of infections caused by Mycoplasma pneumoniae, corynebacterium. Chlamydia trachomatis, Legionella pneumophila, Ureaplasma urealyticum, and Bordetella pertussis. The drug is also active against gram-positive cocci, including pneumococci and beta-lactamase-producing staphylococci (but not MRSA strains). 

---